Pemphigus Therapeutics
1. Wayrilz patent expiration
Treatment: Method for treating adult patients with persistent or chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment, by achieving a platelet count of at least 50,...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9994576 | GENZYME | Substituted Pyrazolo[3,4-D]Pyrimidines As Kinase Inhibitors |
Sep, 2033
(7 years from now) | |
| US9266895 | GENZYME | Substituted Pyrazolo[3,4-D]Pyrimidines As Kinase Inhibitors |
Sep, 2033
(7 years from now) | |
| US8940744 | GENZYME | Pyrazolopyrimidine Compounds As Kinase Inhibitors |
Sep, 2033
(7 years from now) | |
| US11708370 | GENZYME | Solid Forms Of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxyphenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile |
Feb, 2041
(15 years from now) | |
| US9580427 | GENZYME | Kinase Inhibitors |
Mar, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12178818 | GENZYME | Methods For Treating Immune Thrombocytopenia By Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-Yl]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-Yl)Piperazin-1-Yl]Pent-2-Enenitrile |
Oct, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 29, 2030 |
Drugs and Companies using RILZABRUTINIB ingredient
NCE-1 date: 29 August, 2029
Market Authorisation Date: 29 August, 2025
Dosage: TABLET
More Information on Dosage
WAYRILZ family patents
